PPBT Stock Summary and Trading Ideas (Purple Biotech Ltd. - American Depositary Shares | NASDAQ:PPBT)

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Purple Biotech Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol PPBT.

As of February 26, 2026, PPBT stock price declined to $0.50 with 115,709 million shares trading.

PPBT has a beta of 0.22, meaning it tends to be less sensitive to market movements. PPBT has a correlation of 0.00 to the broad based SPY ETF.

PPBT has a market cap of $4.50 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, PPBT traded as high as $47.00 and as low as $.46.

PPBT has underperformed the market in the last year with a price return of -83.1% while the SPY ETF gained +17.2%. PPBT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -37.8% and -16.3%, respectively, while the SPY returned +2.4% and -0.4%, respectively.

PPBT support price is $.49 and resistance is $.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PPBT shares will trade within this expected range on the day.